Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
World game at war: why some European nations have threatened a World Cup boycott 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
LAWRENCE, Mass., April 16, 2018 -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics for the potential treatment of diabetes and related complications, will hold a conference call on Wednesday, April 18, 2018 at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) to discuss recent business developments, including its recent acquisition of CureDM and recently announced intention to acquire Medical Technology Associates II, Inc. Boston Therapeutics management will host the presentation, followed by a question and answer period.
Date: Wednesday, April 18, 2018
Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)
U.S. dial-in: 1-800-263-0877
TOLL/INTERNATIONAL dial-in: 1-323-794-2094
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact ViaVid at toll-free (888) 562-0262 | tel (604) 929-1352.
The conference call will be broadcast live and available for replay at the Investor Relations section of Boston Therapeutics website. A replay of the conference call will be available after 8:00 p.m. Eastern time on the same day through May 02, 2018.
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 2971422
Investor Relations Contact: Loraine V. Upham
About Boston Therapeutics, Inc. www.bostonti.com
Boston Therapeutics, headquartered in Lawrence, MA (OTCQB:BTHE) and with an office in Albuquerque, NM is an innovator in design, development and commercialization of novel compounds to treat diabetes and diabetes related complications. The company has proprietary compounds based on glucose chemistry, peptide chemistry and protein conjugates.
Contact: Boston Therapeutics, Inc.
Loraine Upham, COO
Phone: 603-935-9799
Email: [email protected]
www.bostonti.com
